Establishment Labs to Announce Second Quarter 2020 Financial Results on August 6

Rhea-AI Summary

Establishment Labs Holdings Inc. (Nasdaq: ESTA) will announce its financial results for Q2 2020 on August 6, 2020, post-market. A conference call is scheduled for 5:30 PM ET to discuss these results. The company focuses on women's health, particularly in breast aesthetics and reconstruction, with a product range including the Motiva Implants® and the Divina® 3D Simulation System. Motiva Implants® have received FDA approval and are available in over 80 countries through various distribution channels.

NEW YORK, July 23, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Women’s Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2020 after the market closes on Thursday, August 6, 2020, and will host a conference call at 5:30 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 376-9925 (U.S. and Canada) or (629) 228-0732 (International) and use conference ID number 2649347. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants^®, the centerpiece of the MotivaImagine^® platform. Motiva Implants^® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant^® clinical trial in the United States in April 2018. In addition to Motiva Implants^®, Establishment Labs’ product and technologies portfolio includes the Divina ^® 3D Simulation System and other products and services. Please visit our website for additional information: www.establishmentlabs.com

Investor/Media Contact:
David K. Erickson
Establishment Labs Holdings Inc.
949-447-6671

FAQ

When will Establishment Labs announce its financial results for Q2 2020?

Establishment Labs will announce its financial results for Q2 2020 on August 6, 2020.

What time is the conference call for Establishment Labs' Q2 2020 results?

The conference call will take place at 5:30 PM ET on August 6, 2020.

What products does Establishment Labs focus on?

Establishment Labs focuses on women's health, primarily through breast aesthetics and reconstruction products, including Motiva Implants®.

In how many countries are Motiva Implants® available?

Motiva Implants® are commercially available in more than 80 countries.